These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6321971)

  • 1. Auto- and postsynaptic dopamine receptors in the central nervous system.
    Rebec GV
    Monogr Neural Sci; 1984; 10():207-23. PubMed ID: 6321971
    [No Abstract]   [Full Text] [Related]  

  • 2. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    Costentin J
    Encephale; 1979; 5(2):121-49. PubMed ID: 38958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response of striatonigral substance P systems to a dopamine receptor agonist and antagonist.
    Hanson G; Alphs L; Pradhan S; Lovenberg W
    Neuropharmacology; 1981 Jun; 20(6):541-8. PubMed ID: 6165922
    [No Abstract]   [Full Text] [Related]  

  • 4. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 5. Control of dopamine release by dopamine receptors and by impulse flow as studied by in vivo voltammetry.
    Gonon FG
    Ann N Y Acad Sci; 1986; 473():160-9. PubMed ID: 3492168
    [No Abstract]   [Full Text] [Related]  

  • 6. Dopamine receptors in the central nervous system.
    Creese I; Morrow AL; Leff SE; Sibley DR; Hamblin MW
    Int Rev Neurobiol; 1982; 23():255-301. PubMed ID: 6749737
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 8. Animal models of parkinsonism.
    Silbergeld EK; Calne DB
    Pharmacol Ther; 1981; 12(1):159-66. PubMed ID: 7271971
    [No Abstract]   [Full Text] [Related]  

  • 9. Single unit responses of substantia nigra pars reticulata neurons to apomorphine: effects of striatal lesions and anesthesia.
    Waszczak BL; Lee EK; Ferraro T; Hare TA; Walters JR
    Brain Res; 1984 Jul; 306(1-2):307-18. PubMed ID: 6466980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modification of apomorphine-induced behaviour following chronic swim exercise in rats.
    Dey S; Singh RH
    Neuroreport; 1992 Jun; 3(6):497-500. PubMed ID: 1391756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications.
    Gale K; Casu M
    Mol Cell Biochem; 1981 Sep; 39():369-405. PubMed ID: 6118827
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 14. Dopamine auto- and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists.
    Skirboll LR; Grace AA; Bunney BS
    Science; 1979 Oct; 206(4414):80-2. PubMed ID: 482929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A role of the polysynaptic system of substantia nigra in the cholinergic-dopaminergic equilibrium in the central nervous system.
    Wolfarth S; Dulska E; Gołembiowska-Nikitin K; Vetulani J
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Apr; 302(2):123-31. PubMed ID: 652058
    [No Abstract]   [Full Text] [Related]  

  • 16. The regulation of motor control: an evaluation of the role of dopamine receptors in the substantia nigra.
    Crocker AD
    Rev Neurosci; 1997; 8(1):55-76. PubMed ID: 9402645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synaptic and non-synaptic striatal dopamine D2 receptors: possible implications in normal and pathological behaviour.
    Korf J; Loopuijt LD
    Acta Morphol Neerl Scand; 1988-1989; 26(2-3):177-90. PubMed ID: 2908162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of presynaptic dopamine receptors in regulation of the glutamatergic neurotransmission in rat neostriatum.
    Godukhin OV; Zharikova AD; Budantsev AYu
    Neuroscience; 1984 Jun; 12(2):377-83. PubMed ID: 6146947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rotational behaviour induced by theophylline in 6-OHDA nigrostriatal denervated rats is dependent on the supersensitivity of striatal dopaminergic receptors.
    Casas M; Ferré S; Cadafalch J; Grau JM; Jané F
    Pharmacol Biochem Behav; 1989 Jul; 33(3):609-13. PubMed ID: 2511576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
    Napier TC; Givens BS; Schulz DW; Bunney BS; Breese GR; Mailman RB
    J Pharmacol Exp Ther; 1986 Mar; 236(3):838-45. PubMed ID: 3512819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.